Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This trial is a Multiple center, Open-label, dose escalation Phase Ⅰ clinical study. The
purpose is to evaluate the safety and tolerability of F182112 when infused intravenously (IV)
and determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of
F182112 when infused IV.